A randomized phase ii trial of high-dose chlorambucil vs. fludarabine in patients with advanced B-chronic lymphocytic leukemia

Hematology and Cell Therapy

Volumn 41, Issue 3, 1999, Pages 127-136

  Zittoun, R ^a   De Witte, T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; FLUDARABINE;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LUNG TOXICITY; METHODOLOGY; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHLORAMBUCIL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; VIDARABINE;

EID: 0033051352     PISSN: 12693286     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Rai KR, Sawitsky A Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46: 219
2. Binet JL, Leporrier M, Dighiero G, et al. (1977) A clinical staging system for chronic lymphocytic leukemia. Prognostic significance. Cancer 40: 855
3. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198
4. Baccarani M, Cabol M, Gobbi M, Lauria F, Tura S (1982) Staging of chronic lymphocytic leukemia. Blood 59: 1191
5. Jaksic B, Vitale B (1981) Total Tumor Mass score (TTM): a new parameter in chronic lymphocytic leukaemia. Br J Haematol 49: 405
6. Brugiatelli M, Morabito F, Restifo D, Neri A (1985) Staging of chronic lymphocytic leukemia by total tumor mass (TTM) score. Evaluation of 121 patients. Haematologica 70: 405
7. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA (1988) Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute sponsored Workig Group. American Journal of Hematology 29: 152-163
8. Sawitsky A, Rai KR, Glidewell O, Silver RT and participanting members of CALGB (Cancer and Leukemia Group B) (1977) Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 50: 1049
9. Binet JL, Chastang C, Dighiero G, Travade P and participating members of the French Cooperative Group on chronic lymphocytic leukemia (1986) Effectiveness of "CHOP" regimen in advanced untreated chronic lymphocytic leukemia. Lancet i: 1346
10. Raphael B, Silber R, Moore DF, Oken MM, Click J (1986) Survival duration and complete remission (CR) incidence in advanced chronic lymphocytic leukemia (CLL): a randomized ECOG study [Abstract]. Blood 68, Supp.1: 229a
11. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C (1986) Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 62: 567
12. aksic B, Brugiatelli M (1987) High dose continuous chlorambucil vs. intermittent chlorambucil plus prednisone for treatment of B-CLL. IGCI CLL-01 trial designed and evaluated by total tumor mass score (TTM) and survival. Chronic lymphocytic leukemia: Recent progress, future directions. UCLA Symposia on Molecular and Cellular Biology, New series, Volume 59, Editors: RP Gale & K Rai ; Alan R. Liss, Inc, New York: 1987; 59: 329-336
13. Brugiatelli M (1987) Commentary,in New trends in CLL treatment. Travade P, Chastang P, Dighiero G, Binet J-LJ-L and the Cooperative group on CLL of Society Francaise d'Hematologie. Blood cells 12:499-500
14. Vitale B, Antica M, Benkovic B, Burek B, Jaksic B (1985) Relationship Between Membrane Characteristic, Functional Reactivity of T Lymphocytes and the Progression Rate of B-Cell Chronic Lymphocytic Leukemia. Cancer 56: 1075-1081
15. Jaksic B, Vitale B (1987) Chronic Lymphocytic Leukemia A Model for Studying Immunoproliferative Diseases. Blood cells 12, 12: 281-283, guest editorial
16. Dominis M, Jaksic B (1987) Clinical Relevance of Lymph Node Histology and Lymphocytes Morphology in Chronic Lymphocytic Leukemia. Blood cells 12: 297-313
17. Benkovic B, Burek B, Jaksic B, Vitale B (1987) Modulation of CLL Phenotype by in Vitro Incubation with alpha-1-Thymosin. Blood cells 12: 441-451
18. Keating MJ, Kantarjian H, Talpaz M, Redman J, McCredie KB (1988) Fludarabine therapy in chronic lymphocytic leukemia (CLL). Nouv Rev Fr hematol 30: 461-466
19. Jaksic B, Brugiatelli M (1988) High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL - IGCI CLL-01 trial. Nouv Rev Fr hematol 30: 437-442
20. Grever MR, Kopecky KJ, Coltman CA, Files JC, Greenberg BR, Hutton JJ, Talley R, Von Hoff DD, Balcerzak SP (1988) Fludarabine monophpsphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr hematol 30: 457-459
21. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasques W, Plunkett W, Freireich EJ, McCredie KB (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 74: 19-25
22. Jaksic B, Brugiatelli M (1990) High dose chlorambucil for the treatment of advanced B-chronic lymphocytic leukemia (CLL). Results of two multicentric randomized trials. Blood, 76 [suppl 1]: 284a, abstract
23. Cheson BD (1990) Issues for the future development of fludarabine phosphate. Seminars in Oncology, 17: [Suppl 8], 71-78
24. Freedman LS (1982) Tables of the number of patients required in clinical trials using the logrank test. Statistics in Medicine. 1: 121-129